A two-part, seamless, multicenter, randomized, open-label, adaptive phase II/III study of the blood-brain barrier penetrant ro7771950 versus tucatinib, both in combination with trastuzumab and capecitabine, in patients with pretreated unresectable locally advanced or metastatic her2-positive breast cancer, with or without central nervous system metastases
Phase: Phase II-III clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Oncologia Medica Senologica
Drug: RO7771950
Pathologies: Breast cancer
ClinicalTrials.gov: Read the details about clinical trials
The study is a global Phase II/III adaptive, seamless clinical trial in patients with pretreated, locally advanced unresectable or metastatic HER2-positive breast cancer, with or without central nervous system (CNS) metastases. The study is designed to evaluate the safety and efficacy of a novel investigational drug, RO7771950, administered in combination with trastuzumab and capecitabine, compared with the standard combination of tucatinib, trastuzumab, and capecitabine. Participants will be randomly assigned to one of the treatment arms in order to directly compare the investigational treatment with the standard therapy.
Arm A (Investigational Arm – Phase II): RO7771950 administered orally in combination with trastuzumab and capecitabine.
Arm B (Investigational Arm – Phase II): RO7771950 administered orally in combination with trastuzumab and capecitabine.
Arm C (Control Arm – Phase II/Comparator): tucatinib administered orally in combination with trastuzumab and capecitabine.
In the subsequent phase of the study (Phase III), participants will receive either the selected dose of RO7771950 identified in the initial phase or tucatinib, always in combination with trastuzumab and capecitabine.
The objective of the study is to determine whether RO7771950 in combination with standard therapy can improve survival and disease control compared with current standard treatment.
Last update: 06/08/2026